(Q38136581)

29 August 2017

Basal insulin analogues in the management of diabetes mellitus: What progress have we made? (English)

1 reference

29 August 2017

1 reference

David R Owens

1

1 reference

PubMed ID

24026961

29 August 2017

Glenn Matfin

series ordinal

2

1 reference

PubMed ID

24026961

29 August 2017

Louis Monnier

series ordinal

3

1 reference

29 August 2017

1 February 2014

1 reference

Diabetes - Metabolism: Research and Reviews

29 August 2017

1 reference

29 August 2017

30

1 reference

29 August 2017

2

1 reference

29 August 2017

104-119

1 reference

Expression in Escherichia coli of chemically synthesized genes for human insulin

29 August 2017

1 reference

NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue

21 January 2018

1 reference

In vitro activity of biosynthetic human diarginylinsulin

21 January 2018

1 reference

Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients.

21 January 2018

1 reference

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

21 January 2018

1 reference

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

21 January 2018

1 reference

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes

21 January 2018

1 reference

Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus

21 January 2018

1 reference

Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit

21 January 2018

1 reference

Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine

21 January 2018

1 reference

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

21 January 2018

1 reference

Insulin glargine: a systematic review of a long-acting insulin analogue

21 January 2018

1 reference

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

21 January 2018

1 reference

Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times

21 January 2018

1 reference

Refining basal insulin therapy: what have we learned in the age of analogues?

21 January 2018

1 reference

Fasting and insulin glargine in individuals with type 1 diabetes

21 January 2018

1 reference

The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice

21 January 2018

1 reference

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

Insulin and its analogs: actions via insulin and IGF receptors.

21 January 2018

1 reference

A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review

21 January 2018

1 reference

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

21 January 2018

1 reference

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.

21 January 2018

1 reference

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

21 January 2018

1 reference

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

21 January 2018

1 reference

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.

21 January 2018

1 reference

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

21 January 2018

1 reference

Cost-effectiveness of insulin detemir: a systematic review

21 January 2018

1 reference

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

21 January 2018

1 reference

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

21 January 2018

1 reference

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

21 January 2018

1 reference

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

21 January 2018

1 reference

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

21 January 2018

1 reference

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.

21 January 2018

1 reference

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

21 January 2018

1 reference

Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial

21 January 2018

1 reference

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

21 January 2018

1 reference

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

21 January 2018

1 reference

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial

21 January 2018

1 reference

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

21 January 2018

1 reference

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

21 January 2018

1 reference

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society

21 January 2018

1 reference

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

21 January 2018

1 reference

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

21 January 2018

1 reference

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

21 January 2018

1 reference

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

21 January 2018

1 reference

Insulin degludec improves health-related quality of life (SF-36® ) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials.

21 January 2018

1 reference

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials.

21 January 2018

1 reference

Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use).

21 January 2018

1 reference

A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study

21 January 2018

1 reference

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

21 January 2018

1 reference

Monomeric insulins obtained by protein engineering and their medical implications

21 January 2018

1 reference

Combined Use of Regular and Crystalline Protamine (NPH) Insulins in the Treatment of Severe Diabetes

21 January 2018

1 reference

7 January 2021

1 reference

7 January 2021

Chemical, physical, and biologic properties of biosynthetic human insulin

1 reference

7 January 2021

Insulin preparations with prolonged effect

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

7 January 2021

Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes

1 reference

7 January 2021

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

1 reference

7 January 2021

Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

1 reference

7 January 2021

Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes

1 reference

7 January 2021

Optimizing treatment strategies with insulin glargine in Type 2 diabetes

1 reference

7 January 2021

Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes

1 reference

7 January 2021

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

1 reference

7 January 2021

European Medicines Agency must take account of cardiovascular harm associated with degludec insulin

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.2469

1 reference

29 August 2017

1 reference

PubMed ID

24026961